Cancer NetworkOriginal article
<![CDATA[Trastuzumab Deruxtecan Boosts PFS in First-Line HER2-Mutant NSCLC]]>
Phase 3positiveTrastuzumab DeruxtecanPositive
AI Analysis
Summary
Phase 3 DESTINY-Lung04 trial showed trastuzumab deruxtecan improved progression-free survival in first-line HER2-mutant NSCLC patients. Detailed findings will be presented at a medical meeting and shared with regulatory authorities.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Trastuzumab Deruxtecan boosted PFS in first-line HER2-mutant NSCLC
Importance:7/10
Sentiment:
0.75
Phase_3OncologyNSCLCHER2-mutantPFSDESTINY-Lung04
Related Companies
Read the original article
Published by Cancer Network on August 18, 2026 2:30 PM